Abstract 2085P
Background
Pain symptoms are common among individuals with cancer, often necessitating pain management as part of cancer care. Opioids are thus mainstay in cancer care, notwithstanding the risk of adverse psychosocial sequelae associated with opioid use, including opioid use disorder (OUD). Buprenorphine is commonly used in managing OUD; however, it is unclear whether there are differences in the characteristics of individuals with cancer receiving buprenorphine, and what perioperative outcomes are associated with buprenorphine use.
Methods
We used data from Premier Health Database, a comprehensive electronic healthcare database with over 1,000 contributing healthcare systems and > 10 million inpatient admissions annually. We built a cohort of 616 patients undergoing surgical care for cancer between 2008 and 2020 who received buprenorphine as part of their care, and matched to 6,160 other patients with cancer randomly selected in the database who also underwent surgical care without receiving buprenorphine. We characterized demographic and clinical factors associated with receipt of buprenorphine, and also examined the association between receiving buprenorphine and perioperative outcomes, including length of stay (LOS, in days), hospitalization cost (in US dollars/$), and in-hospital mortality.
Results
Older individuals were less likely to receive buprenorphine (aOR = 0.95; 95% CI 0.94, 0.97), while patients with Medicaid insurance (aOR = 1.76; 95% CI 1.02, 3.03) and Medicare (aOR = 1.49; 95% CI 1.00, 2.24) were more likely to receive buprenorphine, compared to those with private insurance. We also found a significant association between radiation treatment and receipt of buprenorphine (aOR = 2.18; 95% CI 1.31, 3.61). In examining perioperative outcomes associated with receipt of buprenorphine, we found that while receipt of buprenorphine was not associated with in-hospital mortality, it was associated with decreased odds of being discharged home after care (aOR = 0.43; 95% CI 0.30, 0.63), increased hospital LOS (estimate = 3.50; 95% CI 2.79, 4.21), and increased overall cost of care (estimate = $10,353; 95% CI $7,846.54, $12,859.00).
Conclusions
Receipt of buprenorphine is also associated with odds of increased hospital LOS and increased cost of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06